REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Nephrotic Syndrome in ChildrenNephrotic Syndrome, Minimal ChangeNephrotic SyndromeNephrotic Syndrome,Idiopathic
Interventions
DRUG

Prednisone

This study will compare two steroid dosing protocols for the treatment of childhood nephrotic syndrome relapses. The medications used for both intervention and control arms are oral prednisone 5mg tablets (DIN: 00312770) for children able to swallow or use crushed tablets, or oral prednisolone sodium phosphate 5mg base/5mL liquid (DIN: 02245532). Participants hospitalized after study enrollment will be permitted to switch to intravenous methylprednisolone sodium succinate (DIN: 02367955) at the same dose without being considered to have violated their treatment assignment.

Trial Locations (1)

M5G 1E8

RECRUITING

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER